CDK4/6 Inhibitors: What Is the Best Cocktail?

被引：17
|
作者：
Malumbres, Marcos [1 ,2 ]
机构：
[1] Spanish Natl Canc Res Ctr CNIO, Cell Div, Madrid, Spain
[2] Spanish Natl Canc Res Ctr CNIO, Canc Grp, Madrid, Spain
来源：
CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 01期
关键词：
D O I：
10.1158/1078-0432.CCR-18-2177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CDK4/6 inhibitors have shown great potential in the new armamentarium against cancer. However, their effect as single agents is limited, and the hopes are on new combinatory strategies. Recent data suggest that inhibiting mTOR may significantly cooperate with cell- cycle arrest in a variety of cancers.
引用
收藏
页码：6 / 8
页数：3
相关论文
共 50 条
  • [41] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Abeer J. Al-Qasem
    Carla L. Alves
    Sidse Ehmsen
    Martina Tuttolomondo
    Mikkel G. Terp
    Lene E. Johansen
    Henriette Vever
    Luna V. A. Hoeg
    Daniel Elias
    Martin Bak
    Henrik J. Ditzel
    npj Precision Oncology, 6
  • [42] IMMUNOLOGICAL MECHANISMS OF RESISTANCE TO CDK4/CDK6 INHIBITORS IN BREAST CANCER
    Petroni, Giulia
    Gouin, Kenneth
    Martinez, Aitziber Buque
    Knott, Simon
    Formenti, Silvia
    Galluzzi, Lorenzo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A763 - A763
  • [43] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ehmsen, Sidse
    Tuttolomondo, Martina
    Terp, Mikkel G.
    Johansen, Lene E.
    Vever, Henriette
    Hoeg, Luna V. A.
    Elias, Daniel
    Bak, Martin
    Ditzel, Henrik J.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [44] CDK4/6 inhibitors as neoadjuvant treatment in breast cancer-what can we learn?
    Brandao, M.
    Ignatiadis, M.
    ANNALS OF ONCOLOGY, 2018, 29 (12) : 2274 - 2278
  • [45] What's the reality for CDK4/6 inhibitors: Clinical trials or real-world evidence?
    Trapani, Dario
    Mayer, Erica L.
    CANCER, 2023, 129 (07) : 986 - 988
  • [46] CDK4 as a Prognostic Marker of Hepatocellular Carcinoma and CDK4 Inhibitors as Potential Therapeutics
    Lai, Fobao
    Fang, Yingbing
    Cheng, Cong
    Zhong, Xuejing
    Zheng, Wanrong
    Lan, Shiqian
    Peng, Quanshui
    Cai, Xiumei
    Cao, Tiantian
    Zhong, Chengqian
    Gao, Yuzhen
    CURRENT MEDICINAL CHEMISTRY, 2025, 32 (02) : 343 - 358
  • [47] Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6
    Wu, Xuewei
    Yang, Xiaobao
    Xiong, Yan
    Li, Ruitong
    Ito, Takahiro
    Ahmed, Tamer
    Karoulia, Zoi
    Adamopoulos, Christos
    Wang, Hong
    Wang, Li
    Xie, Ling
    Ueberheide, Beatrix
    Aaronson, Stuart
    Chen, Xian
    Sellers, William
    Buchanan, Sean
    Jin, Jian
    Poulikakos, Poulikos I.
    CANCER RESEARCH, 2021, 81 (13)
  • [48] Different expression of CDK4 and CDK6 among B-cell non-Hodgkin lymphomas as a marker of sensitivity to CDK4/6 inhibitors
    Vesela, D.
    Kupcova, K.
    Klener, P.
    Havranek, O.
    Krystof, V.
    Jorda, R.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S78 - S78
  • [49] Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
    Kong, Yan
    Sheng, Xinan
    Wu, Xiaowen
    Yan, Junya
    Ma, Meng
    Yu, Jiayi
    Si, Lu
    Chi, Zhihong
    Cui, Chuanliang
    Dai, Jie
    Li, Yiqian
    Yu, Huan
    Xu, Tianxiao
    Tang, Huan
    Tang, Bixia
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Yan, Xieqiao
    Li, Siming
    Guo, Jun
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6946 - 6957
  • [50] Can CDK4/6 inhibitors cause fatal lung injury?
    Jazieh, Khalid A.
    Budd, G. Thomas
    Dalpiaz, Nancy
    Abraham, Jame
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (11) : 917 - 919
12345